HMGCR and cystic kidney disease: Heterogeneity and pleiotropy test in the examined associations and weak instrument statistics between lipid phenotypes mediated by lipid-lowering drug targets (HMGCR, PCSK9, and NPC1L1) and cystic kidney disease and polycystic kidney disease.